Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 11, 1997, Pages 3570-3573

  Litchfield, W Reid ^a   New, Maria I ^b   Coolidge, Caroline ^a   Lifton, Richard P ^c   Dluhy, Robert G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; DEXAMETHASONE;

ADRENAL CORTEX ADENOMA; ADRENAL HYPERPLASIA; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENETIC SCREENING; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; LABORATORY DIAGNOSIS; MALE; PRIORITY JOURNAL;

EID: 0030722585     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.11.3570     Document Type: Article

References (26)

1. Litchfield WR, Dluhy RG. 1996 Glucorticoid-remediable aldosteronism. Curr Opin Endocrinol Diabetes 3:265-270.
2. Litchfield WR, Dluhy RG, Lifton RP, Rich GM. 1995 Glucocorticoid-remediable aldosteronism. Comp Ther. 21:553-558.
3. Lifton RP, Dluhy RG, Powers M, et al. 1992 Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 2:66-74.
4. Lifton RP, Dluhy RG, Powers M, et al. 1992 A chimaeric 11 beta-hydroxylase / aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 355:262-265.
5. Ganguly A, Chavarri M, Luetscher JA, Dowdy AJ. 1977 Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethasone administration. J Clin Endocrinol Metab. 44:775-779.
6. Wenting GJ, Man In't Veld AJ, Derkx FH, Brummelen PV, Schalekamp MADH. 1978 ACTH-dependent aldosterone excess due to adrenocortical adenoma: a variant of primary aldosteronism. J Clin Endocrinol Metab. 46:326-335.
7. Hoefnagels WH, Drayer JI, Smals AG, Benraad TJ, Kloppenborg PW. 1980 Nocturnal, daytime, and postural changes of plasma aldosterone before and during dexamethasone in adenomatous and idiopathic aldosteronism. J Clin Endocrinol Metab. 51:1330-1334.
8. Bell G, Karam J, Rutler W. 1981 Polymorphic DNA region adjacent to the 5′endo of the human insulin gene. Proc Natl Acad Sci USA. 78:5759-5763.
9. Liddle GW. 1960 Tests of pituitary-adrenal suppressibility in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab. 20:1539-1561.
10. Liddle GW, Estep HL, Kendall JWJ, Williams WCJ, Townes AW. 1959 Clinical application of a new test of pituitary reserve. J Clin Endocrinol Metab. 19:875-894.
11. Lins PE, Adamson U. 1986 Plasma aldosterone-plasma renin activity ratio. A simple test to identify patients with primary aldosteronism. Acta Endocrinol (Copenh). 113:564-569.
12. Stowasser M, Bachmann AW, Jonsson JR, Tunny TJ, Klemm SA, Gordon RD. 1995 Clinical, biochemical, and genetic approaches to the detection of familial hyperaldosteronism type I. J Hypertens. 13:1610-1613.
13. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. 1995 A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 207:565-571.
14. Sutherland DJ, Ruse JL, Laidlaw JC. 1966 Hypertension, increased aldosterone secretion, and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 95:1109-1119.
15. Giebink GS, Gotlin RW, Biglieri EG, Katz FH. 1973 A kindred with familial glucocorticoid suppressible aldosteronism. J Clin Endocrinol Metab. 36:715-723.
16. Oberfield SE, Levine LS, Stoner E, et al. 1981 Adrenal glomerulosa function in patients with dexamethasone-suppressibie hyperaldosteronism. J Clin Endocrinol Metab. 53:158-164.
17. Woodland E, Tunny TJ, Hamlet SM, Gordon RD. 1985 Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressibie hyperaldosteronism. Clin Exp Pharmacol Physiol. 12:245-248.
18. Kato S, Haji M, Yanase T, Nawata H, Kato K, Ibayashi H. 1988 A case of glucocorticoid-suppressiote hyperaldosteronism with aldosterone producing adenoma. Endocrinol Jpn. 35:311-320.
19. Ganguly A, Grim CE, Bergstein J, Brown RD, Weinberger MH. 1981 Genetic and pathophysiologic studies of a new kindred with glucocorticoid-suppressible hyperaldosteronism manifest in three generations. J Clin Endocrinol Metab. 53:1040-106.
20. Stockigt JR, Scoggins BA. 1987 Long term evolution of glucocorticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab. 64:22-26.
21. Newton MA, Laragh JH. 1968 Effects of glucocorticoid administration on aldosterone excretion and Plasma renin in normal subjects, in essential hypertension and in primary aldosteronism. J Clin Endocrinol Metab. 28:1014-1022.
22. Schambelan M, Brust NL, Chang BCF, Slater KL, Biglieri EG. 1976 Circadian rhythm and effect of posture on plasma aldosterone concentration in primary aldosteronism. J Clin Endocrinol Metab. 43:115.
23. Slaton PE, Schambelan M, Biglieri EG. 1969 Stimulation and suppression of aldosterone secretion in patients with an aldosterone producing adenoma. J Clin Endocrinol Metab. 29:239-250.
24. Stockigt JR, Scoggins BA. 1987 Long term evolution glucocoticoid-suppressible hyperaldosteronism. J Clin Endocrinol Metab. 64:22-26.
25. Connell JM, Kenyon CJ, Corrie JE, Fraser R, Watt R, Lever AF. 1986 Dexamethasone-suppressibie hyperaldosteronism. Adrenal transition cell hyperplasia? Hypertension. 8:669-676.
26. Ulick S, Chan CK, Gill Jr JR, et al. 1990 Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 71:1151-1157.